The demand in senior years to maintain peak physical fitness has led to the emergence of the longevity industry, which caters to the needs of old and active seniors, professor at IISc, and convenor of the Longevity India Initiative, and lead investigator, ICMR Centre for Advanced Research on Aging, writes
The world is facing uncertainties—from tariffs to wars. But amidst all of this, India's economic growth, advancements, and diplomatic outreach have brought it to the forefront of international discussions, the MD & CEO of NSE writes
For India to take a leap into developing sport further, we need to treat it as a social culture, and not just a pursuit for medals, India's first individual gold medallist writes
The Trump disruption is an opportunity to build consensus on the need for wide-ranging reforms and their execution, the editorial director of Business Standard, and author, writes
For the Anniversary Special this year, Forbes India invited industry stalwarts to weigh in on how disruptions can be opportunities for renewal and growth
The MD & CEO of Volkswagen-Skoda India talks about gaining market share in India, the significance of safety features, and investing Rs 10,000 crore over the next decade
Chaudhry, who had announced while taking over as CEO his ambition of moving the needle in Axis Bank's position, says "if we create the right platforms, keep adding and building on it over a period of time, we can get there"
It was worth the time and effort, Axis Bank's CEO and MD Amitabh Chaudhry tells Forbes India, and the move pit the bank across the spectrum
Under Amitabh Chaudhry, Axis Bank is focusing on leadership in select areas and identifying growth engines. Can he chew all he is biting off?
Private businesses that give away all profits and also succeed as businesses are scarce; An eleemosynary aim would seem to be even more out of place on Wall Street, where "greed is good" is the mantra
It used to be that Chinese drug development was largely about creating "me too" drugs for the local market. But over the past 10 years, with Beijing focussed on building a native biotech industry, US-trained Chinese scientists have returned home and started innovating instead of mimicking